Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410056 | 1.00 | KDM4E (0.47) | KDM4EALDH1A1ALOX5GAAMAPT | |
| SCHEMBL17295280 | 0.88 | CA2 (0.42) | KDM4EALDH1A1ALOX5GAAMAPT | |
| SCHEMBL4599785 | 0.83 | CYP1A2 (0.53) | KDM4EALDH1A1ALOX5GAAMAPT | |
| SCHEMBL29545673 | 0.83 | CYP4F2 (0.42) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL509144 | 0.83 | CYP4F2 (0.42) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1128476 | 0.81 | TAAR1 (0.52) | KDM4EALDH1A1GAAMAPTBACE1 | |
| SCHEMBL29410058 | 0.81 | TDP1 (0.39) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2298160 | 0.81 | TDP1 (0.39) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14555727 | 0.81 | IGF1R (0.40) | KDM1AKCNH2KDM1BPARP1 | |
| SCHEMBL29331986 | 0.81 | IGF1R (0.40) | KDM1AKCNH2KDM1BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240173332-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240165243-A1 | EGFR DEGRADERS AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-2623499-A1 | 1,2,4-TRIAZOLONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197217-A1 | 1, 2, 4-TRIAZOLONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130197217-A1 | 1, 2, 4-TRIAZOLONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130197217-A1 | 1, 2, 4-TRIAZOLONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-08-01 | — | — | US | disclosed |
| WO-2013075083-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2011103063-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-08-25 | — | — | WO | disclosed |
| CN-101600700-A | Novel 2-aminooxazolines as TAAR1 ligands for CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-12-09 | — | — | CN | disclosed |
| EP-0563981-B1 | Cis-1,4-substituted 2-butene derivative | CHISSO CORP (JP) | 1997-01-22 | — | — | EP | disclosed |
| US-5401434-A | Cis-1,4-substituted 2-butene derivative | CHISSO CORPORATION (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0563981-A2 | Cis-1,4-substituted 2-butene derivative | Chisso Corporation (JP) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173332-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING RESPIRATORY SYNCYTIAL VIRUS INFECTION | GABRA3, GABRA6, GABRA1 | KDM4E 1905/4885ALDH1A1 2754/4885ALOX5 2916/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | KDM4E 43/4885ALDH1A1 1178/4885ALOX5 3462/4885 |
| US-20130197217-A1 | 1, 2, 4-TRIAZOLONE DERIVATIVE | AVPR1B, AVPR1A, AVPR2 | KDM4E 2260/4885ALDH1A1 1322/4885ALOX5 3233/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | KDM4E 4023/4885ALDH1A1 2057/4885ALOX5 2198/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | KDM4E 2318/4885ALDH1A1 3514/4885ALOX5 4826/4885 |
| US-20240165243-A1 | EGFR DEGRADERS AND METHODS OF USE | EGFR, ERBB2, ERBB3 | KDM4E 1405/4885ALDH1A1 3601/4885ALOX5 4795/4885 |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KDM4E 3289/4885ALDH1A1 917/4885ALOX5 3196/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | KDM4E 4023/4885ALDH1A1 2057/4885ALOX5 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.